Scanlan Jacqueline
Known title: Executive VP & Chief HROCIK: 0001713517
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Axalta Price Target to $36, Maintains Neutral Rating. UBS lowered its price target for Axalta to $36 while keeping a neutral stance. The company also announced the date for its third-quarter 2026 earnings call. These updates provide new context as Axalta trades near its 52-week low, with the stock currently sitting above a key support level.
Transaction History
| FMC | ▼ Sell | Tax Withholding | 5,137 | $49K | 9/28/2026 | View on chart |
| FMC | ▼ Sell | Tax Withholding | 1,404 | $21K | 2/23/2026 | View on chart |
| FMC | ▲ Buy | Grant | 42,232 | $0 | 2/19/2026 | View on chart |
| FMC | ▼ Sell | Open Market | 3,790 | $129K | 9/29/2025 | View on chart |
| FMC | ▼ Sell | Tax Withholding | 5,177 | $174K | 9/29/2025 | View on chart |
| FMC | ▼ Sell | Open Market | 1,510 | $57K | 8/18/2025 | View on chart |
| FMC | ▲ Buy | Grant | 9,084 | $0 | 2/21/2025 | View on chart |
| FMC | ▲ Buy | Grant | 583 | $0 | 2/18/2025 | View on chart |
| FMC | ▲ Buy | Grant | 28 | $0 | 2/18/2025 | View on chart |
| FMC | ▼ Sell | Open Market | 4,529 | $270K | 11/11/2024 | View on chart |
| FMC | ▼ Sell | Tax Withholding | 5,132 | $339K | 9/27/2024 | View on chart |
| FMC | ▲ Buy | Grant | 4,799 | $0 | 2/20/2024 | View on chart |
| FMC | ▲ Buy | Grant | 33,511 | $0 | 9/27/2023 | View on chart |
| AXTA | ▼ Sell | Open Market | 17,008 | $501K | 8/9/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 16,266 | — | 7/27/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 6,910 | $221K | 7/27/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 2,873 | — | 6/14/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,221 | $40K | 6/14/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 11,545 | — | 6/14/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 4,905 | $159K | 6/14/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 3,238 | — | 2/15/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,529 | $45K | 2/15/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 2,873 | — | 6/14/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,221 | $30K | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FMC completes minority stake with Tessenderlo, sets Q3 earnings date
FMC Corporation and Tessenderlo Group have completed a minority equity investment, adding a new strategic partner to the business. The company also announced the date for its third‑quarter 2026 earnings release and the accompanying webcast. Recent commentary noted that the stock has fallen sharply, making it appear inexpensive relative to sales, a point that may be of interest given its current price near a long‑standing support level.
FMC completes minority stake with Tessenderlo, sets Q3 earnings date. FMC Corporation and Tessenderlo Group have completed a minority equity investment, adding a new strategic partner to the business. The company also announced the date for its third‑quarter 2026 earnings release and the accompanying webcast. Recent commentary noted that the stock has fallen sharply, making it appear inexpensive relative to sales, a point that may be of interest given its current price near a long‑standing support level.